Carmen Criscitiello· @CarmenCriscit · X·· 1 day agoScore70
Body · original
Great to see my longtime friend @antgiorda present FOURLIGHT-1 at #ESMO26: atirmociclib + fulvestrant improved PFS vs investigator's choice after prior CDK4/6 (9.4 vs 6.6 mo, HR 0.60). Encouraging data after CDK4/6. #ESMOAmbassadors @myESMO
98 views · 6 likes · 1 repost · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Carmen Criscitiello · x.com